Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 525

Results For "CHI"

5473 News Found

Govt revises NLEM and slashes prices of 39 drugs
Policy | September 04, 2021

Govt revises NLEM and slashes prices of 39 drugs

At present 18 per cent of the local pharmaceutical market is under government's price control


HCG acquires oncology labs and divests stake in Strand Life Sciences
Healthcare | September 04, 2021

HCG acquires oncology labs and divests stake in Strand Life Sciences

The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.


Covid-19 vaccine clinical trial for people with autoimmune disease
Drug Approval | September 03, 2021

Covid-19 vaccine clinical trial for people with autoimmune disease

Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study


CII awards Excellence in Energy efficiency to Sai Life Sciences API unit
Sustainability | September 03, 2021

CII awards Excellence in Energy efficiency to Sai Life Sciences API unit

The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL


Union Minister Mansukh Mandaviya chairs meet on eradicating TB
Policy | September 02, 2021

Union Minister Mansukh Mandaviya chairs meet on eradicating TB

Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya


Janssen announces U.S. FDA approval of Invega Hafyera
Drug Approval | September 02, 2021

Janssen announces U.S. FDA approval of Invega Hafyera

Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months


Morpen Laboratories to transfer its medical devices business to a wholly owned subsidiary
News | September 02, 2021

Morpen Laboratories to transfer its medical devices business to a wholly owned subsidiary

The revenues and profits derived from the new subsidiary will be consolidated in the parent company


Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage
News | September 01, 2021

Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage

PPH is associated with almost 20 per cent of maternal mortality in India


Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1
News | September 01, 2021

Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1

The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio